Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

4D Pharma posts "exciting" development results from MicroRx

Tue, 16th Jun 2015 08:33
Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx.The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis.The group also identified bacteria that have "therapeutically relevant" effects in an industry standard model of multiple sclerosis.Furthermore, its pre-clinical work showed "clear efficacy" in preventing the development of multiple sclerosis.Chief scientific officer Alex Stevenson said: "These results are an exciting development in the progress of live biotherapeutics."To potentially treat a disease such as multiple sclerosis with an oral capsule of therapeutically functional bacteria would be a huge step forward in the treatment of this disease."Shares were up 3.76% to 897.5p on Tuesday at 08:32.

Related News

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM
15 Feb 2023

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June ...

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil
3 Feb 2023

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

DDDD.L News

4d Pharma buoyed by Texas cancer treatment partnership
7 Jan 2019

4d Pharma buoyed by Texas cancer treatment partnership

(Sharecast News) - 4d Pharma's shares enjoyed a boost on Monday after entering a collaboration with a specialist cancer unit at the University of Texa...

4D Pharma Partners With Cancer Center For Cancer Treatment
7 Jan 2019

4D Pharma Partners With Cancer Center For Cancer Treatment

LONDON (Alliance News) - 4D Pharma PLC on Monday said it has partnered with the University of Texas MD Anderson Cancer Center to evaluate its live bio...

4d Pharma "Not Aware Of Matter" Responsible For Drop In Share Price
12 Dec 2018

4d Pharma "Not Aware Of Matter" Responsible For Drop In Share Price

LONDON (Alliance News) - 4d Pharma PLC on Wednesday noted a recent fall in its share price, but said is not aware of any company-related reasons for t...

4d Pharma Interim Loss Holds Steady Despite Rise In R&D Spending
28 Sep 2018

4d Pharma Interim Loss Holds Steady Despite Rise In R&D Spending

LONDON (Alliance News) - 4d Pharma PLC on Friday said its loss widened only marginally in the first half of the year, despite significantly higher exp...

4d Pharma losses little changed as trials begin
28 Sep 2018

4d Pharma losses little changed as trials begin

(Sharecast News) - First-half losses grew slightly at live biotherapeutics developer 4d Pharma as first-half research and development expenses jumped ...

Positive top-line results for 4D Pharma's Thetanix
24 Sep 2018

Positive top-line results for 4D Pharma's Thetanix

(Sharecast News) - Biotherapeutics company 4D Pharma announced positive top-line results for its Phase 1b study of 'Thetanix' in paediatric patients w...

4d Pharma Reports Positive Results From Phase Ib Study Of Thetanix
24 Sep 2018

4d Pharma Reports Positive Results From Phase Ib Study Of Thetanix

LONDON (Alliance News) - 4d Pharma PLC on Monday said its phase Ib study of Thetanix in paediatric patients with Crohn's disease achieved its primary ...

Janus Henderson Increases Stake In 4d Pharma To 5.2% (ALLISS)
12 Jun 2018

Janus Henderson Increases Stake In 4d Pharma To 5.2% (ALLISS)

LONDON (Alliance News) - 4d Pharma PLC said Janus Henderson Group PLC increased stake in the pharmaceutical company to 5.2% after a transaction on Tue...